Novo Nordisk Shares Are Trading Lower Following a Report Suggesting a Study Linked Ozempic to an Increased Risk of a Rare Form of Vision Loss.
Novo Nordisk Shares Are Trading Lower Following a Report Suggesting a Study Linked Ozempic to an Increased Risk of a Rare Form of Vision Loss.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.